MCRB · Seres Therapeutics, Inc.
$4.65
-0.15 (-3.13%)
At close · Jul 29
Going-concern doubt
— flagged May 5, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed May 5, 2026
Market Cap
$46.01M
Shares
9.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.65
Open$4.74
Day$4.65–4.90
52W$4.59–29.98
Avg vol 30d109K
Short int303K · 3.2% float · 2.0d
Short vol65%
Last earningsNov 5, 2025
DataJan 2020–Jul 2026
Filing10-Q · May 5
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 5, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 20.7 · elevated
Equity put/call 0.61
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
−29%
below
RSI (14)
29
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−41%
trailing
6-month return
−66%
trailing
YTD return
−69%
this year
Relative strength
−72%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $7 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
5 of 34 funds reported for Jun 30 · net +551 sh shares · +1 new
Insider flow
Distributing
Net -$3.6K over 90 days · 100% sells
Short interest
Rising
3.17% of float · ▲ +92.9% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 5-yr range
Squeeze score
58
elevated · 0–100
Fundamentals
Free cash flow
$865.0K
Balance sheet
$64.2M
net debt
Quant / Vol
risk profile
Volatility
97%
annualized · 1-yr
Max drawdown
−84%
past year
ATR
10.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Sep 30, 2024
Payments
· 2025
Initiated
$73.5M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
−29%
Bearish
RSI (14)
29
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $7 › 200d $11 — 200d above 50d
Institutional flow
Accumulating
5 of 34 funds reported for Jun 30 · net +551 sh shares · +1 new
Insider flow
Distributing
Net -$3.6K over 90 days · 100% sells
Short interest
Rising
3.17% of float · ▲ +92.9% MoM · 2.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
34 holders — mid 5-yr range
Price context
position in its 52-week range
52-wk low $5
Now $5 · 0%
52-wk high $30
vs 200-day avg -59%
vs 50-day avg -29%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MCRB
this stock
Seres Therapeutics, Inc.
|
$46.01M | -68.8% | -95.0% | — | 3.2% |
|
ONC
BeOne Medicines Ltd.
|
$472.90B | +7.7% | +22179.2% | 962.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$122.67B | +6.6% | +46.2% | 28.7 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$72.91B | -9.8% | +20.8% | 17.0 | 3.3% |
|
ARGX
Argenx SE
|
$54.57B | +4.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MCRB | -11.9% | -41.1% | -65.9% | -41.1% | -68.8% |
| SPY | -2.4% | -2.3% | +6.3% | -2.3% | +7.0% |
| vs SPY | -9.5% | -38.7% | -72.2% | -38.7% | -75.7% |